A delegation led by the Director-General of the National Agency of Drug and Food Control of the Republic of Indonesia paid a visit to Minhai.

Release date:

2018-08-08

Author:

Zhang Qian, Department of International Cooperation

Source:


Abstract

On August 7, 2018, a delegation of twelve, including Dr. Ir. Penny Kusumastuti Lukito, Director General of the National Agency of Drug and Food Control of the Republic of Indonesia (hereinafter referred to as “Indonesia’s FDA”), along with Deputy Directors Dra. Reri Indriani, Dra. Rr Maya Gustina Andarini, Director of the Drug Registration Division Togi Junice Hutadjulu, and Director of the Cooperation Division Diana ES Sutikno, paid a visit to Beijing Minhai Biotechnology Co., Ltd. Company General Manager Zheng Haifa, Executive Deputy General Manager Liu Jiankai, and other company leaders extended a warm welcome to the Indonesian FDA delegation on behalf of Minhai Biotechnology.

  On August 7, 2018, a delegation of twelve, including Dr. Ir. Penny Kusumastuti Lukito, Director General of the National Agency of Drug and Food Control of the Republic of Indonesia (hereinafter referred to as “Indonesia’s NAFDAC”), Deputy Directors General Dra. Reri Indriani and Dra. Rr Maya Gustina Andarini, Director of the Drug Registration Division Togi Junice Hutadjulu, and Director of the Cooperation Division Diana ES Sutikno, paid a visit to Beijing Minhai Biotechnology Co., Ltd. Mr. Zheng Haifa, General Manager, and Mr. Liu Jiankai, Executive Deputy General Manager, along with other company leaders, extended a warm welcome to the Indonesian NAFDAC delegation on behalf of Minhai Biotechnology.

  Company executives briefed the Indonesian Food and Drug Authority delegation on the company’s operations, including the development of novel vaccines, international collaborations, and overseas vaccine registration. The delegation then toured the company’s quality control and other departments.

  Dr. Ir. Penny Kusumastuti Lukito, Head of Indonesia’s Food and Drug Authority, expressed full recognition of the company’s product R&D capabilities and overall strength, and stated that she hopes this visit will help facilitate and accelerate the entry of Minhai Biotech’s vaccine products into the Indonesian market, thereby fostering deeper cooperation between Minhai Biotech and Indonesia.

  Minhai Biologics has expressed its interest in engaging in multi‑level, multi‑faceted cooperation with Indonesia, with the aim of further providing high‑quality, affordable vaccine products to the country and making a greater contribution to expanding China’s vaccine exports and advancing the development of China’s biopharmaceutical industry.

 

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09